| 11-PIR-11
|
The BEACON Study (Breast Cancer Outcomes With NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician ... |
| 2010-01
|
Phase II study of Bendamustine and Ofatumumab in patients with Diffuse Large B-Cell Lymphoma who are poor candidates for R-CHOP chemotherapy |
| 391101
|
A Phase 1 Open Label Study to Access the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BAX69 in Subjects with Maglignant Solid Tumors |
| B 43
|
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Du ... |
| B 47
|
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorub ... |
| BIND-014-001
|
Open-Label, Randomized, A PHASE 1 OPEN LABEL, SAFETY, PHARMACOKINETIC AND PHARMACODYNAMIC DOSE ESCALATION STUDY OF BIND-014, GIVEN BY IV INFUSION TO P ... |
| BO25126/APHINITY
|
A Randomized Multicenter, Double-blind, Placebo-controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo Versus Chemotherapy Plus Trastuzum ... |
| BO25499
|
A Phase I, Open Label, Parallel Group, Pharmacokinetic Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Norm ... |
| BRE 166
|
Use of the PRO Onc Assay to Assess HER2 Amplification and Activation in Patients With Metastatic Breast Cancer Whose Tumors Are HER2-Negative by Stand ... |
| BRE 186
|
Phase II Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy |
| BRE 197
|
A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast ... |
| C05013
|
An Open-Label, Randomized, Phase 2 Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Patients with Non- Germi ... |
| CA204-006
|
A Phase 3, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myelom ... |
| CD-ON-MEDI-573-1030
|
A Phase 1b/2 Randomized Study of MEDI-573 in Combination With an Aromatase Inhibitor (AI) Versus AI Alone in Women With Metastatic Breast Cancer (MBC) |
| CNS 13
|
Phase I/II Study of the Combination of BKM120 and Bevacizumab in Patients With Refractory Solid Tumors (Phase I) and Relapsed/Refractory Glioblastoma ... |
| CO-338-010
|
A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients with gBRCA Mutation Breast Cancer or O ... |
| D2270C00005
|
A Phase I, Open-label, Multicentre, Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered Orally ... |
| D3610C00003
|
A Phase Ib, Multicentre Study of AZD5363 Monotherapy to Assess the Anti-tumour Activity, Safety, Tolerability and Pharmacokinetics in Metastatic Castr ... |
| D4320C00001
|
A Randomised Double Blind Phase II Trial to Evaluate the Efficacy of Two Doses of Fostamatinib in Patients with Relapsed or Refractory Diffuse Large B ... |
| DLM-10-001
|
Open-label, Single Arm, Safety and Tolerability Dose Escalation Study of DAG in Patients With Recurrent Malignant Glioma |
| E7050-701
|
Open-Label, Randomized, Phase 2 Study of E7050 in Combination with Sorafenib versus Sorafenib Alone as First Line Therapy in Hepatocellualr Carcinoma |
| E7050-702
|
An Open-Label, Multicenter, Randomized, Phase II Study of E7050 in Combination with Cetuximab versus Cetuximab Alone in the Treatment of Platinum-Resi ... |
| E7389-702
|
An Open-Label, Multicenter, Randomized Phase Ib/II Study of Eribulin Mesylate Administered in Combination with Gemcitabine Plus Cisplatin Versus Gemci ... |
| EMR200592-001
|
Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination with TH-302 Compared with Gemcitabine in Combinatio ... |
| FRF4998g
|
An Open-Label, Multicenter, Phase I Trial of the Safety and
Pharmacokinetics of Escalating Doses of DFRF4539A in Patients with Relapsed or Refractor ... |
| GDC4950g
|
Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of GDC-0941 or GDC-0980 with Fulvestrant versus Fulvestrant in Advanced or Metastatic Brea ... |
| GI 134
|
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With ... |
GI 148
View Slide
|
A Phase II Study of Hsp90 Inhibitor AUY922 for the Treatment of Patients With Refractory Gastrointestinal Stromal Tumor |
| GO25632
|
A Phase III, Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Bevacizumab and associated Biomark ... |
| GO27826
|
Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Vemurafenib (RO5185426) Adjuvant Therapy in Patients with Surgically-Resected Cutaneo ... |
| GO27834
|
A Randomized, Non-Comparative. Open-Label, Multicenter, Phase II Trial Evaluation the Safety and Activity of DCDT2980S in Combination with Rituximab o ... |
| GO27912
|
Phase II, Double-Blind, Placebo-Controlled, Randomized Study Evaluating the Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/B ... |
| GS-US-295-0203
|
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With FOLFIRI as Second Line Treat ... |
| GS-US-312-0116
|
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS 1101 (CAL-101) in Combination With Rituximab fo ... |
| GS-US-312-0117
|
A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent GS 1101 (CAL 101) as Therapy f ... |
| GS-US-324-0101
|
A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine as First Line ... |
| HHBB
|
A Phase 1 Dose Escalation Study of LY2940680 in patients with Advance Cancer (Lilly HHBB) |
| I4T-MC-JVBB
|
A Randomized, Double-Blind, Multicenter Phase 3 Study of Irinotecan, Folinic Acid, and 5 Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patient ... |
| INCB 18424-258
|
An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis (PMF), Post Essential Thrombocythem ... |
| INK128-003
|
A Phase I, Open Label, Dose Escalation Study of Oral Administration of INK128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects Wi ... |
| LUN 186
|
Phase II trial of Preoperative Pemetrexed and Carboplatin in Patients with Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer |
| LUN196
|
Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients with Stage IIIB/IV Non–Small-Cel ... |
| MDV3100-08
|
A Phase 1 Open-Label, Dose Escalation Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Enzalutamide (formerly MDV3100) in Patients w ... |
| ML28257
|
ML28257/BRE208 An Observational Study of Treatment Patterns and Outcomes in Patients with Her2 Positive Metastatic Breast Cancer |
| ML28442
|
FOLFOXIRI/Bevacizumab Regimens (Concurrent and Sequential) versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer |
| MM 23
|
Phase II Study for the Evaluation of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients with Multiple Myeloma Wh ... |
| MM 27
|
Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma |
| OAM4971g
|
A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating Efficacy and Safety of Onartuzumab (Metmab) in Combination Wit ... |
| OGX-011-12
|
Randomized Phase 3 Study Comparing Cabazitaxel/Prednisone in Combination with Custirsen
Cabazitaxel/Prednisone for Second-Line Chemotherapy in Meta ... |
| P5
|
Statin Polyp Prevention Trial in Patients with Resected Colon Cancer |
| PMT4979g
|
An Open-Label, Phase I, Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients with Locally Advanced or Metastatic Solid ... |
| RV-FOL-GELARC-0683C
|
Phase III Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab + Lenalidomide versus Rituximab + Chemotherapy Followed by Ritux ... |
| SGI-110-01
|
Phase 2 Study of Two Subcutaneous Regimens of SGI-110 in Subjects with Intermediate or High-Risk Myelodysplastic Syndromes or Acute Myelogenous Leukem ... |
| SNDX-275-0110
|
A Phase I Study to Assess the Food Effect on the Pharmacokinetics of Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic ER+ Breas ... |
| TDM4529g
|
BRE 155 TDM4529g/BO25430: AN OPEN-LABEL, MULTICENTER EXTENSION STUDY OF TRASTUZUMAB EMTANSINE ADMINISTERED AS A SINGLE AGENT OR IN COMBINATION WITH OT ... |
| TGR-1202-101
|
A Phase I Dose Escalation Study Evaluating the Safety and Efficacy of TGR-1202 in Patients with Relapsed or Refractory Hematologic Malignancies |
| TS-P04834
|
Phase 3, Randomized, Double-Blind Study of the Safety and Efficacy of Rolapitant for the Prevention of CINV in Subjects Receiving Moderately Emetogeni ... |
| VEG11338
|
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects With ... |
| VS-6063-101
|
A Phase I/IB Study of Paclitaxel in Combination With VS-6063, A Focal Adhesion Kinase Inhibitor, In Subjects With Advanced Ovarian Cancer |
| X82-CLI-101
|
A Phase I, First in Human Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of X-82 in Subjects with Advanced Solid Tum ... |